Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 15 de 15
Filter
1.
J Int Med Res ; 34(6): 640-7, 2006.
Article in English | MEDLINE | ID: mdl-17294996

ABSTRACT

The chronic leukaemias include two distinct chronic neoplastic disease states, namely chronic myelogenous leukaemia (CML) and chronic lymphocytic leukaemia (CLL). The aim of this study was to assess the utility of leucocyte count, neutrophil percentage and absolute lymphocyte count from differential complete blood count analyses as indicators of the possible presence of CML and CLL. Blood counts from 102 patients with histopathologically confirmed CML and CLL were compared with counts for 858 cancer-free control subjects. Optimal cut-off values were identified by selecting values with the highest sensitivity-specificity combination for each blood count parameter for the two diseases. The results indicated that any individual with mature-appearing lymphocytes at a level > 6.65 x 10(9)/l in the peripheral blood should be examined further for CLL, and that any individual with a leucocyte count > 18.0 x 10(9)/l or a neutrophil proportion > 72.6% should be investigated for CML.


Subject(s)
Blood Cell Count , Leukemia, Lymphocytic, Chronic, B-Cell/diagnosis , Leukemia, Myelogenous, Chronic, BCR-ABL Positive/diagnosis , Female , Humans , Leukemia, Lymphocytic, Chronic, B-Cell/blood , Leukemia, Myelogenous, Chronic, BCR-ABL Positive/blood , Male , Sensitivity and Specificity
2.
Neurol Sci ; 24(1): 34-6, 2003 Apr.
Article in English | MEDLINE | ID: mdl-12754655

ABSTRACT

Myasthenia gravis is an autoimmune disorder that affects the neuromuscular junction and leads to weakness of the skeletal muscles. Associated autoimmune diseases such as systemic lupus erythematosus, rheumatoid arthritis and pernicious anaemia are present in approximately 5% of the myasthenic patients. This report presents a 64-year-old man with autoimmune haemolytic anemia associated with myasthenia gravis and thymoma. The patient developed a severe Coomb's positive autoimmune haemolytic anaemia, which was resistant to treatment with large doses of prednisone. Haemolytic anaemia entered remission one month following thymectomy, and the patient has maintained a normal haemoglobin and a negative Coomb's test without the need for steroid or immunosuppressive therapy. In conclusion, thymectomy may induce a striking improvement of therapyresistant autoimmune haemolytic anemia in patients with MG and thymoma, but in terms of remission, a long follow-up is needed as autoimmune diseases can show spontaneous fluctuations.


Subject(s)
Anemia, Hemolytic, Autoimmune/surgery , Myasthenia Gravis/surgery , Thymoma/surgery , Thymus Neoplasms/surgery , Anemia, Hemolytic, Autoimmune/complications , Anemia, Hemolytic, Autoimmune/drug therapy , Humans , Male , Middle Aged , Myasthenia Gravis/complications , Myasthenia Gravis/drug therapy , Thymectomy , Thymoma/complications , Thymoma/drug therapy , Thymus Neoplasms/complications , Thymus Neoplasms/drug therapy
3.
Emerg Med J ; 19(5): 458-9, 2002 Sep.
Article in English | MEDLINE | ID: mdl-12205007

ABSTRACT

Only three cases of non-cardiogenic pulmonary oedema secondary to high dose verapamil ingestion have been described in the literature. This report describes two girls, who developed pulmonary oedema in the course of massive dose verapamil ingestion (total of 6000 mg and 7200 mg). Left ventricule size and function was normal on transthoracic echocardiograms in both of these patients. They were treated successfully with mechanical ventilatory support. The report emphasises that this fatal complication may be seen with verapamil overdose and underlying mechanisms and therapeutic approach are discussed.


Subject(s)
Pulmonary Edema/chemically induced , Verapamil/poisoning , Adult , Drug Overdose , Female , Humans , Poisoning/complications , Respiration, Artificial , Suicide, Attempted
5.
Clin Rheumatol ; 21(3): 211-4, 2002 Jun.
Article in English | MEDLINE | ID: mdl-12111626

ABSTRACT

Alpha-interferon (alpha-IFN) is implicated in a Behçet's disease (BD)-like syndrome observed in a small number of chronic myeloid leukemia (CML) patients. The effect of alpha-IFN on neutrophil adhesion and phagocytosis in CML patients, BD patients and healthy volunteers was investigated to clarify the reason for this observation. Ten subjects were studied for each group by incubating neutrophils with various doses of alpha-IFN. Basal neutrophil adhesions for CML patients, BD patients and healthy volunteers were similar. However, BD patients had greater basal phagocytosis than CML patients, and both groups had greater basal phagocytosis than healthy volunteers. Neutrophil adhesion and phagocytosis of CML patients increased following incubation with higher doses of alpha-IFN, and phagocytosis approached the high levels observed with BD neutrophils. This study provides evidence that alpha-IFN activates neutrophils in CML patients in a dose-dependent manner, and leads to a neutrophil function profile that resembles BD.


Subject(s)
Antineoplastic Agents/adverse effects , Behcet Syndrome/blood , Interferon-alpha/adverse effects , Leukemia, Myelogenous, Chronic, BCR-ABL Positive/blood , Neutrophils/physiology , Phagocytosis/drug effects , Adult , Cell Adhesion/drug effects , Dose-Response Relationship, Drug , Female , Humans , Interferon alpha-2 , Male , Middle Aged , Recombinant Proteins , Reference Values
7.
Biol Blood Marrow Transplant ; 6(4): 370-4, 2000.
Article in English | MEDLINE | ID: mdl-10917572

ABSTRACT

In general, tuberculosis (Tb) is rarely seen in allogeneic stem cell transplant (alloSCT) recipients, but this observation has been challenged in developing countries such as Turkey, where Tb infection is more prevalent than in Europe and the US. In this retrospective study, we report on the incidence of Tb infections in 351 alloSCT recipients at 4 bone marrow transplantation units in Turkey over the last 10 years. The frequency of Tb in alloSCT recipients after allografting (5 of 351) was far greater than that in the general population (35.4 per 100,000). Of the 351 patients who underwent alloSCT, 77 who received isoniazid (INH) chemoprophylaxis for 6 months did not develop posttransplantation Tb. However, 5 of the remaining 274 patients who received no chemoprophylaxis developed Tb a median of 12 months (range, 10-47 months) after allografting. Antituberculosis therapy resulted in complete recovery in all cases. In 2 additional patients who were found to have active pulmonary Tb at the time of transplantation, alloSCT was delayed until the infections were treated. Infections of mycobacteria other than Mycobacterium tuberculosis were not observed. The number of patients who received and tolerated INH may not be sufficient for firm conclusions, but the data suggest that, in countries where Tb is prevalent, pre- and posttransplantation follow-up for Tb and the use of INH prophylaxis should be considered.


Subject(s)
Hematopoietic Stem Cell Transplantation/adverse effects , Tuberculosis, Pulmonary/etiology , Adolescent , Adult , Antitubercular Agents/administration & dosage , Antitubercular Agents/toxicity , Female , Graft vs Host Disease , Humans , Isoniazid/administration & dosage , Isoniazid/toxicity , Leukemia, Myelogenous, Chronic, BCR-ABL Positive/complications , Leukemia, Myelogenous, Chronic, BCR-ABL Positive/therapy , Leukemia, Myeloid, Acute/complications , Leukemia, Myeloid, Acute/therapy , Liver Diseases/etiology , Male , Middle Aged , Prevalence , Retrospective Studies , Survival Rate , Transplantation, Homologous/adverse effects , Tuberculosis, Pulmonary/drug therapy , Tuberculosis, Pulmonary/epidemiology , Turkey/epidemiology
8.
Haematologica ; 85(5): 464-9, 2000 May.
Article in English | MEDLINE | ID: mdl-10800160

ABSTRACT

BACKGROUND AND OBJECTIVE: Hepatocyte growth factor (HGF) is known to augment the effects of stem cell factor, interleukin-3, granulocyte-macrophage colony-stimulating factor (GM-CSF), erythropoetin, and granulocyte colony-stimulating factor, all of which are involved in hematopoiesis. HGF is also known to have a role in immune responses. The aim of this study was to investigate whether HGF is involved in the development of dendritic cells (DC) from CD34+ bone marrow cells. DESIGN AND METHODS: CD34+ cells obtained from three healthy donors were incubated in various combinations of HGF, GM-CSF, and tumor necrosis factor (TNF) for 12 days. Developing cell populations were analyzed for surface markers, morphology and functional capacities by flow cytometry, light microscopy and mixed lymphocyte reaction, respectively. RESULTS: Incubation with HGF alone generated greater number of dendritic cells from CD34+ bone marrow cells than incubation with GM-CSF, or a combination of GM-CSF with TNF. HGF was also found to potentiate the effect of GM-CSF on DC and monocyte development. The effects of HGF were inhibited by the concurrent use of TNF. INTERPRETATION AND CONCLUSIONS: HGF appears to be a significant factor in the development of dendritic cells from CD34+ bone marrow cells.


Subject(s)
Antigens, CD34/analysis , Bone Marrow Cells/cytology , Bone Marrow Cells/immunology , Cell Differentiation/drug effects , Dendritic Cells/cytology , Hepatocyte Growth Factor/physiology , Antigens, CD/metabolism , Bone Marrow Cells/drug effects , Flow Cytometry , Granulocyte-Macrophage Colony-Stimulating Factor/pharmacology , Hepatocyte Growth Factor/pharmacology , Humans , Lymphocyte Culture Test, Mixed , Time Factors , Tumor Necrosis Factor-alpha/pharmacology
9.
Turk J Haematol ; 17(1): 33-5, 2000 Mar 05.
Article in English | MEDLINE | ID: mdl-27265762

ABSTRACT

Chronic a-interferon use has been reported to cause a variety of neurotoxic side effects. This case summary suggests the possibility of a new neurotoxic side effect of normal pressure hydrocephalus following chronic a-interferon use.

10.
Leuk Lymphoma ; 33(5-6): 567-72, 1999 May.
Article in English | MEDLINE | ID: mdl-10342584

ABSTRACT

In order to investigate the relationship between aberrant marker expression and DNA ploidy, 61 adult patients with acute leukemia (39 AML and 22 ALL) were studied. Aberrant marker expression was observed in 20 patients (16/39 of AML and 4/22 of ALL patients). In flow cytometric DNA analysis aneuploidy was observed in 18 patients (9/39 of AML and 9/22 of ALL patients). The incidence of aneuploidy in patients with aberrant marker expression was 35% whereas this was 26.8% in patients without aberrant marker expression. Furthermore, 7 patients with aberrant marker expression showed an aneuploid, double G0/G1 peaks appearance whereas the remaining 11 patients with aberrant marker expression had euploid DNA content. Double G0/G1 appearance was not observed in patients without aberrant marker expression. Further analyses revealed that this did not correlate with apoptosis. All 7 patients, who had both aberrant marker expression and double G0/G1 peak had a poor clinical outcome with a short survival and all died within three months whereas three-months survival was 67% for AML, 69% for ALL patients and 81% for patients with aberrant marker expression respectively (p<0.01). Our data indicate that the evaluation of the DNA ploidy in patients with aberrant marker expression may be of prognostic importance.


Subject(s)
Aneuploidy , Biomarkers, Tumor , DNA, Neoplasm/genetics , Leukemia/genetics , Acute Disease , Adolescent , Adult , G1 Phase , Humans , Leukemia/pathology , Leukemia/physiopathology , Middle Aged , Predictive Value of Tests , Prognosis , Resting Phase, Cell Cycle
12.
Br J Haematol ; 103(4): 1061-3, 1998 Dec.
Article in English | MEDLINE | ID: mdl-9886319

ABSTRACT

Fifty-seven adult patients with idiopathic thrombocytopenic purpura (ITP) were treated with either conventional-dose prednisolone (CDP) (1 mg/kg/d, 36 patients) or high-dose methylprednisolone (HDP) (30 mg/kg/d, 21 patients), as first-line treatment. Patients in the HDP arm responded more rapidly (4.7 v 8.4 d), with a higher response rate (80% v 52.7%), and without severe side-effects. One quarter of the patients (3/12) who were non-responsive to CDP achieved complete remission when they were treated with HDP. The findings suggest that HDP may be a more effective first-line treatment than CDP for adult ITP, and it may also be preferred for life-threatening cases of ITP. However, these results must be confirmed by a randomized study prior to any change in the current practice of employing CDP as first-line treatment for adult ITP.


Subject(s)
Glucocorticoids/administration & dosage , Methylprednisolone/administration & dosage , Purpura, Thrombocytopenic, Idiopathic/drug therapy , Adolescent , Adult , Aged , Female , Humans , Male , Middle Aged , Prednisolone/therapeutic use
13.
Eur J Haematol ; 58(1): 14-21, 1997 Jan.
Article in English | MEDLINE | ID: mdl-9020368

ABSTRACT

Thalassaemia intermedia, defined as homozygous beta-thalassaemia in which patients are not transfusion-dependent, covers a wide range of clinical severity. It may arise because one or more genetic factors ameliorate the otherwise severe phenotype of thalassaemia major. Exactly which and how many such mutations are necessary to produce a thalassaemia intermedia phenotype is incompletely understood, although such information would be useful both clinically and for prenatal diagnosis. We examined DNA from 28 patients with thalassaemia intermedia resident in London and 28 matched patients with thalassaemia major, for 3 types of genetic modifying factors, namely; mild beta-thalassaemia mutations, the upstream XmnI G-gamma globin gene polymorphism, and alpha-globin gene deletions. The results show that the number of alleviating mutations present has a large influence on the phenotype of patients with homozygous beta-thalassaemias. A single alleviating mutation was present in 56% of thalassaemia intermedia subjects compared with 26% of thalassaemia major subjects. Two alleviating mutations were present in 33% of thalassaemia intermedia subjects compared with 1 thalassaemia major subject. No patients with thalassaemia major had 3 alleviating mutations, in contrast to 11% of those with thalassaemia intermedia. Although the findings did not account for the full range of phenotypic variation, such information is of potential value both in the clinical management and the prenatal diagnosis of homozygous beta-thalassaemia.


Subject(s)
Mutation , beta-Thalassemia/genetics , Adolescent , Adult , Aged , Child , Child, Preschool , Female , Genotype , Humans , Male , Middle Aged , Syndrome , beta-Thalassemia/physiopathology
15.
Arch Dis Child ; 72(5): 408-12, 1995 May.
Article in English | MEDLINE | ID: mdl-7618906

ABSTRACT

Twenty eight patients with thalassaemia intermedia and their parents were interviewed using specifically designed questionnaires to evaluate psychosocial burden. Hospital notes were analysed for clinical burden. A wide variation was found for both patients and parents, ranging from virtually unaffected to severely affected. Normal sexual function and setting up a family were mentioned by patients and parents as being particularly important for quality of life. Over half (58%) of the patients had problems with sexual maturation and functioning, and continuous monitoring of all patients with thalassaemia intermedia by a paediatric endocrinologist is therefore strongly indicated. Most parents said, in light of their experiences, that they would opt for prenatal diagnosis and termination of affected pregnancies even if a genotype predicting the mild form of disorder were discovered.


Subject(s)
Family Health , Prenatal Diagnosis , Social Isolation , beta-Thalassemia/psychology , Abortion, Legal/psychology , Adolescent , Adult , Aged , Attitude to Health , Child , Child, Preschool , Female , Fetal Diseases/diagnosis , Humans , Male , Middle Aged , Parents/psychology , Pregnancy , beta-Thalassemia/complications , beta-Thalassemia/diagnosis
SELECTION OF CITATIONS
SEARCH DETAIL
...